Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort study.

Eighty-five percent of males and 38% of females who began at 600 mg/d remained at that level. Evaluation of Overall Survival, High- Versus Low-Dose Imatinib In an analysis of overall survival by starting imatinib dose, a small benefit of 5.7 months was observed for the high- over low-dose group and did not reach statistical significance (77 versus 71.3 months, P = 0.336, HR = 1.25; Fig. 2 ).

also in 111,027 other papers